# Single Ascending Dose PK, Oral Bioavailability and Food Effect Study in Healthy Male Volunteers

> **NCT03852446** · EARLY_PHASE1 · COMPLETED · sponsor: **NewLink Genetics Corporation** · enrollment: 56 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Indoximod HCL (F2) tablets
- **DRUG:** Indoximod base formulation
- **OTHER:** Placebo
- **DRUG:** Indoximod HCL (F2) tablets

## Key facts

- **NCT ID:** NCT03852446
- **Lead sponsor:** NewLink Genetics Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-05
- **Primary completion:** 2018-03-05
- **Final completion:** 2018-08-14
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2020-05-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03852446

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03852446, "Single Ascending Dose PK, Oral Bioavailability and Food Effect Study in Healthy Male Volunteers". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03852446. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*